Business Wire

Splunk Machine Learning Helps Recursion Pharmaceuticals Treat Genetic Diseases

SAN FRANCISCO--(BUSINESS WIRE)--Splunk Inc. (NASDAQ: SPLK), first in delivering “aha” moments from machine data, today announced biotechnology company Recursion Pharmaceuticals is using Splunk® ...
NJBIZ

Bayer, Recursion collaborate on digital drug discovery for fibrotic diseases

Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...
Business Wire

Dr. Imran S. Haque, Biology Machine Learning Expert, Joins Recursion as VP of Data Science

SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...
Bloomberg L.P.

Roche Signs Machine-Learning Neuroscience Deal With Recursion

Roche Holding AG sealed a decade-long collaboration deal with U.S. biotech Recursion Pharmaceuticals Inc. to use machine learning to search out potential drugs for neuroscience and cancer. The deal ...
C&EN

Roche signs drug discovery pact with machine-learning firm Recursion

Recursion, a company that uses machine learning for drug discovery, is partnering with Roche and its subsidiary Genentech to identify novel drug targets and develop drugs against them. The firms will ...
Zacks.com on MSN

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow ...